Herantis Pharma Oyj
OMXH:HRTIS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.2
1.855
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one HRTIS stock under the Base Case scenario is 0.17 EUR. Compared to the current market price of 1.32 EUR, Herantis Pharma Oyj is Overvalued by 87%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Herantis Pharma Oyj
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for HRTIS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Herantis Pharma Oyj
Balance Sheet Decomposition
Herantis Pharma Oyj
Current Assets | 3.6m |
Cash & Short-Term Investments | 3.5m |
Receivables | 117k |
Other Current Assets | 42k |
Current Liabilities | 1.6m |
Accounts Payable | 784k |
Accrued Liabilities | 753k |
Other Current Liabilities | 46k |
Non-Current Liabilities | 25k |
Long-Term Debt | 25k |
Earnings Waterfall
Herantis Pharma Oyj
Revenue
|
0
EUR
|
Operating Expenses
|
-193.6k
EUR
|
Operating Income
|
-193.6k
EUR
|
Other Expenses
|
-418.5k
EUR
|
Net Income
|
-612.2k
EUR
|
Free Cash Flow Analysis
Herantis Pharma Oyj
EUR | |
Free Cash Flow | EUR |
HRTIS Profitability Score
Profitability Due Diligence
Herantis Pharma Oyj's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Herantis Pharma Oyj's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
HRTIS Solvency Score
Solvency Due Diligence
Herantis Pharma Oyj's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Herantis Pharma Oyj's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HRTIS Price Targets Summary
Herantis Pharma Oyj
According to Wall Street analysts, the average 1-year price target for HRTIS is 1.48 EUR with a low forecast of 0.71 EUR and a high forecast of 2.31 EUR.
Dividends
Current shareholder yield for HRTIS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Herantis Pharma Oyj engages in the research and development of biopharmaceutical products. The company is headquartered in Espoo, Etela-Suomen. The company went IPO on 2014-06-11. Leveraging research about protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis develops a pipeline of regenerative biological and gene therapies for high impact diseases. These include CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, Lymfactin VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that aims to slow, stop, or even reverse the course of diseases, and bring innovation to these diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one HRTIS stock under the Base Case scenario is 0.17 EUR.
Compared to the current market price of 1.32 EUR, Herantis Pharma Oyj is Overvalued by 87%.